These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12736082)

  • 1. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy.
    Chin RL; Sherman WH; Sander HW; Hays AP; Latov N
    J Neurol Sci; 2003 Jun; 210(1-2):19-21. PubMed ID: 12736082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients.
    Tobinick E; Davoodifar S
    Curr Med Res Opin; 2004 Jul; 20(7):1075-85. PubMed ID: 15265252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists.
    Alshekhlee A; Basiri K; Miles JD; Ahmad SA; Katirji B
    Muscle Nerve; 2010 May; 41(5):723-7. PubMed ID: 20405504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.
    Baughman RP; Lower EE; Bradley DA; Raymond LA; Kaufman A
    Chest; 2005 Aug; 128(2):1062-47. PubMed ID: 16100213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept: a review of its use in rheumatoid arthritis.
    Jarvis B; Faulds D
    Drugs; 1999 Jun; 57(6):945-66. PubMed ID: 10400407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
    de Vlam K; Lories RJ
    Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure.
    Bozkurt B; Torre-Amione G; Warren MS; Whitmore J; Soran OZ; Feldman AM; Mann DL
    Circulation; 2001 Feb; 103(8):1044-7. PubMed ID: 11222463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
    Moreland LW; Schiff MH; Baumgartner SW; Tindall EA; Fleischmann RM; Bulpitt KJ; Weaver AL; Keystone EC; Furst DE; Mease PJ; Ruderman EM; Horwitz DA; Arkfeld DG; Garrison L; Burge DJ; Blosch CM; Lange ML; McDonnell ND; Weinblatt ME
    Ann Intern Med; 1999 Mar; 130(6):478-86. PubMed ID: 10075615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Our experience with etanercept in the treatment of psoriasis.
    Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
    Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.
    Yazici Y; Erkan D; Lockshin MD
    Clin Exp Rheumatol; 2000; 18(6):732-4. PubMed ID: 11138337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.
    Iyer S; Yamauchi P; Lowe NJ
    Br J Dermatol; 2002 Jan; 146(1):118-21. PubMed ID: 11841377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.